3C Therapeutics: Making degrader-antibody conjugates plug and play

3C’s core bet is that degrader-antibody conjugates will become a widely used modality across cancer and other indications, creating demand for a flexible, plug-and-play chemistry core that can upgrade protein degraders with the precision of antibody-delivery.

Spun out of chemistry work in David Perrin’s lab at the University of British Columbia, Vancouver-based 3C Therapeutics Inc. has built a trifunctional “TriCore” linker that lets it design degrader payloads for antibody conjugation instead of retrofitting existing degrader modalities such as proteolysis targeting chimeras (PROTACs). ...